The total survival rate increased by more than twice, and then Ding Pharma's first tumor electric field treatment products on the market.

(Health Times reporter Kong Tianqiu) February 28, re-Ding Pharmaceutical announced that the first tumor electric field treatment products (commodity name Optune ®) listed in Hong Kong. Tumor electric field therapy is a treatment that uses a specific electric field frequency to interfere with cell division, inhibit tumor growth, and kill cancer cells affected by electric field.
Optune ®, the world's first and only FDA-approved tumor electric field treatment product, has been approved in the United States, Europe, Japan and other countries and regions for the treatment of glioblastoma, while a number of other clinical trials for solid tumor indications are being conducted simultaneously.
glioblastoma is the most common and invasive adult brain tumor, is a very malignant disease, clinical treatment is very difficult, the patient's five-year survival rate is less than 5%, less than 1/3 of the five-year survival rate of lung cancer. "This innovative treatment for tumor electric field therapy has been shown to change the clinical treatment of glioblastoma, " said Liu Huilong, deputy director of oncology at the Seventh Medical Center of the PLA General Hospital. "
" before, the standard treatment of glioblastoma mainly to surgery, but the recurrence rate is very high, nearly 100%, postoperative combination of radiotherapy and tMZ chemotherapy, to delay recurrence play a role, but not a cure, the patient's median survival is only about 15 months. From the long-term effect of treatment, whether it is surgery or chemotherapy, the effect of treatment is very unsatisfactory. Liu Huilong said.
Liu Huilong explained that clinically showed that compared to the use of monomylysis alone, the tumor electric field treatment Optune ® and the combination of timozole to treat new glioblastoma, the total five-year survival rate of patients increased from 5% to 13%, more than double, the patient's median total survival from 16 months to 20.9 months.
" compared to previous surgical, radiotherapy and drug treatment and other means, tumor electric field therapy is more convenient and noninvasive, adverse reactions are small, its effectiveness has been rigorously clinically verified. Improving the quality of life and extending survival is a very good choice for patients. Liu Huilong added.
the emergence of tumor electric field therapy, which brings new hope to the treatment of glioblastoma, but also provides patients with a new treatment option. Liu Huilong said, from the perspective of clinical applications, we are now seeing basically some foreign literature report research data. There is a lack of domestic clinical research data, especially in mainland China. In the future, it is also necessary to further conduct further clinical research and evaluation on the safety and effectiveness of tumor electroblastoma patients in China, get our own research data, and better guide our clinical practice in the field of glioblastoma treatment.
.